Current Update on Retinoblastoma

Houston, Samuel K.; Murray, Timothy G.; Wolfe, Stacey Quintero; Fernandes, C. E.

doi:10.1097/iio.0b013e3182010f29

Cited by 87 publications

(74 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 The 5-year survival rate of pediatric patients with RB in European and American countries is over 95%, and the 3-year survival rate of pediatric patients with RB in China is 93.7%. 6,7 The eye salvage rates of pediatric patients at stages A, B, and C in the International Intraocular Retinoblastoma Classification in other countries can reach as high as 90%. 8 The enucleation rate of pediatric patients with RB in China has decreased from 91.46% to approximately 42.22% in recent years.…”

Section: Introductionmentioning

confidence: 99%

Quality of life in children with retinoblastoma after enucleation in China

Zhang

Gao

Shen

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Objective: To study the quality of life of Chinese pediatric patients with retinoblastoma (RB) after enucleation and the influencing factors.Methods: A questionnaire survey was performed on 71 cases of pediatric patients with RB after enucleation and 80 cases of healthy children, using the Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL TM 4.0). Results:The social dimension scores, school dimension scores, and total scores for the PedsQL TM 4.0 among the pediatric patients with RB were statistically significantly lower than those of healthy children. The influencing factors were unilateral/bilateral affected eyes, diagnosis age, and ocular prosthesis satisfaction. Conclusion:Early discovery, timely treatment, increased eye salvage rate, and cosmetic effects of ocular prosthesis were key factors for increasing the quality of life of pediatric patients with RB.Attention should be paid to the health, social, and school development of pediatric patients with RB.

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of life in children with retinoblastoma after enucleation in China

Zhang

Gao

Shen

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…34 Combined with vascular targeting therapies that increase hypoxia, glycolytic inhibitors and anti-angiogenic agents may be used synergistically for a greater reduction in tumor burden. 35 Combination of 2-DG and Anecortave Acetate provided advanced tumor control and reduction in tumor burden compared to 2-DG alone. 36 …”

Section: Anecortave Acetate and Liposomal Clodronatementioning

confidence: 99%

New Hopes in Retinoblastoma Treatment

Turhan¹

2014

UHOD

View full text Add to dashboard Cite

Survival rates of retinoblastoma have increased dramatically during the last decade. The current major treatment modalities for retinoblastoma include enucleation, intravenous chemoreduction, external beam therapy, focal treatments (such as brachytherapy and transpupillary thermotherapy), subconjunctival chemotherapy and selective ophthalmic artery chemotherapy. Although current treatment modalities have improved survival rates as well as eye salvage, new treatment modalities are expected to arise in the near future, since above mentioned non-targeted treatments have extensive side effects. Recent advances in genetic analysis of retinoblastoma 1 (RB1) mutations and pathways leading to retinoblastoma may provide vital information for the development of new targeted therapies which are less toxic. Keywords: Genetics, Retinoblastoma, RB1 mutation, Targeted treatments ÖZET Retinoblastom Tedavisinde Yeni UmutlarSon on yılda retinoblastomda sağ kalım oranları dramatik olarak artmıştır. Enükleasyon, intravenöz kemoredüksiyon, dışsal ışın radyoterapi, fokal tedaviler (brakiterapi ve transpupiller termoterapi gibi), subkonjonktival kemoterapi, selektif oftalmik arter kemoterapi retinoblastomda kullanılan önemli tedavi modaliteleridir. Yeni tedavi seçenekleri göz küresinin kurtarılması ve sağkalım oranlarında iyileşme sağlamasına rağmen, özgül olmayan kemoterapi ajanlarının yaygın yan etkileri nedeniyle gelecekte yeni tedavi modalitelerine ihtiyaç duyulmaktadır. Retinablastom 1RB1 mutasyonlarının gen analizi ve retinoblastom oluşumunu sağlayan yolaklardaki son gelişmeler; daha az toksisitesi olan hedeflenmiş terapilerin gelişiminde önemli bilgiler sağlayacaktır.

show abstract

“…At present, the main treatments are systemic chemotherapy combined with local treatment (1). Although the efficacy of chemotherapy has recently improved, the long-term systemic chemotherapy can cause severe side effects, such as bone marrow suppression, ototoxicity, renal toxicity and other adverse reactions that affect the child's quality of life (5,6). These side effects are particularly serious because children are in an active phase of development during the treatment.…”

Section: Introductionmentioning

confidence: 99%

“…After 24 h, cell numbers were counted in the culture using Counter Star with the Automated Cell Counter software. In addition, 1x10 5 RB-Y79 and RB-R cells were cultured with carboplatin at 40 µg/ml, respectively. The cytotoxicity was analysed as described above.…”

Section: Cytotoxicity Assay On Rb-resistant Cells (Rb-r)mentioning

confidence: 99%

See 1 more Smart Citation

Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells

et al. 2013

View full text Add to dashboard Cite

Abstract. Retinoblastoma (RB) is a challenging disease that affects mostly young children. Chemical therapy has been shown to have limitations during clinical practice, principally because of the ability of RB to become resistant to the treatment. Nevertheless, chemotherapy is still the main treatment for RB, and immunotherapy has become a promising treatment for most solid tumors with fewer side effects than traditional therapies. In this study, we explored the antitumor effects of cytokine-induced killer (CIK) cells co-cultured with dendritic cells (DCs) pulsed with complete tumor antigens (DC-Ag). Cytotoxicity and specificity were evaluated on an RB cell line (RB-Y79), on a human normal retina cell line (hTERT-RPE1) and a carboplatin-resistant RB cell line. Our results showed that CIK differentiation and cytotoxicity were enhanced by co-culturing CIKs with DC-Ag. Moreover, the co-culture improved the CIK proliferation rate by increasing IL-6 and decreasing IL-10 levels in the culture medium. Furthermore, the use of DC-Ag-CIK cells had little effect on normal retinal cells but high cytotoxicity on RB cells even on carboplatinresistant retinoblastoma cells. This is the first study showing that DC cells pulsed with the complete tumor antigen improve proliferation, differentiation and cytotoxic activity of CIKs specific not only for RB but also for the chemotherapy-resistant form of the malady. Thus highly efficient immunotherapy based on DC-Ag-CIK cells may be a potential effective and safe mean of treating RB especially to patients where traditional chemical therapy has failed.

show abstract

Current Update on Retinoblastoma

Cited by 87 publications

References 51 publications

Quality of life in children with retinoblastoma after enucleation in China

Quality of life in children with retinoblastoma after enucleation in China

New Hopes in Retinoblastoma Treatment

Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells

Contact Info

Product

Resources

About